MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

United Therapeutics Corp

Fermé

SecteurSoins de santé

306.66 -1.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

297.87

Max

312.24

Chiffres clés

By Trading Economics

Revenu

-7.8M

301M

Ventes

-13M

736M

P/E

Moyenne du Secteur

12.506

63.778

BPA

6.19

Marge bénéficiaire

40.943

Employés

1,305

EBITDA

6.3M

424M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+23.18% upside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.7B

14B

Ouverture précédente

308.42

Clôture précédente

306.66

Sentiment de l'Actualité

By Acuity

7%

93%

3 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

United Therapeutics Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 oct. 2024, 15:14 UTC

Principaux Mouvements du Marché

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 janv. 2025, 10:30 UTC

Actualités

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparaison

Variation de prix

United Therapeutics Corp prévision

Objectif de Prix

By TipRanks

23.18% hausse

Prévisions sur 12 Mois

Moyen 384.64 USD  23.18%

Haut 460 USD

Bas 293 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

8

Achat

3

Maintien

1

Vente

Score Technique

By Trading Central

307.64 / 312.61Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

3 / 386Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.